190 related articles for article (PubMed ID: 36242618)
1. Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): prospective pilot study.
Stoop TF; van Veldhuisen E; van Rijssen LB; Klaassen R; Gurney-Champion OJ; de Hingh IH; Busch OR; van Laarhoven HWM; van Lienden KP; Stoker J; Wilmink JW; Nio CY; Nederveen AJ; Engelbrecht MRW; Besselink MG;
Langenbecks Arch Surg; 2022 Dec; 407(8):3487-3499. PubMed ID: 36242618
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113).
Guggenberger KV; Bley TA; Held S; Keller R; Flemming S; Wiegering A; Germer CT; Kimmel B; Kunzmann V; Hartlapp I; Anger F
Eur J Radiol; 2023 Jun; 163():110834. PubMed ID: 37080059
[TBL] [Abstract][Full Text] [Related]
3. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy.
van Veldhuisen E; Vogel JA; Klompmaker S; Busch OR; van Laarhoven HWM; van Lienden KP; Wilmink JW; Marsman HA; Besselink MG
HPB (Oxford); 2018 Jul; 20(7):605-611. PubMed ID: 29475787
[TBL] [Abstract][Full Text] [Related]
4. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
[TBL] [Abstract][Full Text] [Related]
5. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
6. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
7. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
8. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
9. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery.
Donahue TR; Isacoff WH; Hines OJ; Tomlinson JS; Farrell JJ; Bhat YM; Garon E; Clerkin B; Reber HA
Arch Surg; 2011 Jul; 146(7):836-43. PubMed ID: 21768431
[TBL] [Abstract][Full Text] [Related]
10. Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study).
Fischerova D; Pinto P; Burgetova A; Masek M; Slama J; Kocian R; Frühauf F; Zikan M; Dusek L; Dundr P; Cibula D
Ultrasound Obstet Gynecol; 2022 Feb; 59(2):248-262. PubMed ID: 33871110
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of whole-body diffusion-weighted MRI (WB-DWI/MRI) in diagnosis, staging and follow-up of gastric cancer, in comparison to CT: a pilot study.
De Vuysere S; Vandecaveye V; De Bruecker Y; Carton S; Vermeiren K; Tollens T; De Keyzer F; Dresen RC
BMC Med Imaging; 2021 Feb; 21(1):18. PubMed ID: 33546626
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
[TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced ultrasound: Improving the preoperative staging of hepatocellular carcinoma and guiding individual treatment.
Zhang XY; Luo Y; Wen TF; Jiang L; Li C; Zhong XF; Zhang JY; Ling WW; Yan LN; Zeng Y; Wu H
World J Gastroenterol; 2014 Sep; 20(35):12628-36. PubMed ID: 25253968
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
15. Utility of Diffusion-Weighted MRI for Detection of Locally Recurrent Pancreatic Cancer After Surgical Resection.
Shin N; Kang TW; Min JH; Hwang JA; Kim YK; Kim YY; Han IW; Kim K
AJR Am J Roentgenol; 2022 Nov; 219(5):762-773. PubMed ID: 35611918
[No Abstract] [Full Text] [Related]
16. Vascular involvement and resectability of pancreatic ductal adenocarcinoma on contrast-enhanced MRI: comparison with pancreatic protocol CT.
Noda Y; Kawai N; Kaga T; Ishihara T; Hyodo F; Kato H; Kambadakone AR; Matsuo M
Abdom Radiol (NY); 2022 Aug; 47(8):2835-2844. PubMed ID: 35760922
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
18. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.
Wittel UA; Lubgan D; Ghadimi M; Belyaev O; Uhl W; Bechstein WO; Grützmann R; Hohenberger WM; Schmid A; Jacobasch L; Croner RS; Reinacher-Schick A; Hopt UT; Pirkl A; Oettle H; Fietkau R; Golcher H
BMC Cancer; 2019 Oct; 19(1):979. PubMed ID: 31640628
[TBL] [Abstract][Full Text] [Related]
19. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.
Cassinotto C; Mouries A; Lafourcade JP; Terrebonne E; Belleannée G; Blanc JF; Lapuyade B; Vendrely V; Laurent C; Chiche L; Wagner T; Sa-Cunha A; Gaye D; Trillaud H; Laurent F; Montaudon M
Radiology; 2014 Oct; 273(1):108-16. PubMed ID: 24960211
[TBL] [Abstract][Full Text] [Related]
20. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Vogel JA; Rombouts SJ; de Rooij T; van Delden OM; Dijkgraaf MG; van Gulik TM; van Hooft JE; van Laarhoven HW; Martin RC; Schoorlemmer A; Wilmink JW; van Lienden KP; Busch OR; Besselink MG
Ann Surg Oncol; 2017 Sep; 24(9):2734-2743. PubMed ID: 28560601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
